Bone disease in CKD: A focus on osteoporosis diagnosis and management

American Journal of Kidney Diseases

Volumn 64, Issue 2, 2014, Pages 290-304

  Miller, Paul D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

bone histomorphometry; bone specific alkaline phosphatase; Chronic kidney disease mineral and bone disorder (CKD MBD); Index Words; osteoporosis; parathyroid hormone (PTH); renal failure

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID;

ARTICLE; BONE BIOPSY; CHRONIC KIDNEY DISEASE; DISEASE MARKER; FRAGILITY FRACTURE; HUMAN; MORPHOMETRICS; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS;

BONE HISTOMORPHOMETRY; BONE-SPECIFIC ALKALINE PHOSPHATASE; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER (CKD-MBD); OSTEOPOROSIS; PARATHYROID HORMONE (PTH); RENAL FAILURE;

BONE DENSITY; BONE DISEASES; DISEASE MANAGEMENT; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84905104130     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.12.018     Document Type: Article

References (127)

1. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy JAMA 285 6 2001 785 795
2. P.D. Miller Guidelines for the diagnosis of osteoporosis: T-scores vs fractures Rev Endocr Metab Disord 7 2006 75 89
3. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group World Health Organ Tech Rep Ser 843 1994 1 129
4. L.J. Melton III How many women have osteoporosis, now? J Bone Miner Res 10 2 1995 175 177
5. S. Baim, N. Binkley, and J.P. Bilezikian et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference J Clin Densitom 11 1 2008 75 91
6. M.L. Bouxsein Non-invasive measurements of bone strength: promise and peril J Musculoskelet Neuronal Interact 4 4 2004 404 405
7. E. Seeman Bone quality: the material and structural basis of bone strength J Bone Miner Metab 26 1 2008 1 8
8. ® and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 2008 385 397
9. S.R. Majumdar, F.A. McAlister, and J.A. Johnson et al. Interventions to increase osteoporosis treatment in patients with 'incidentally' detected vertebral fractures Am J Med 125 2012 929 936
10. B.C. Lentle, J.P. Brown, A. Khan, W.D. Leslie, J. Levesque, and D.J. Lyons Scientific Advisory Council of Osteoporosis Canada; Canadian Association of Radiologists. Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures Can Assoc Radiol J 58 2007 27 36
11. Y.T. Chen, P.D. Miller, E. Barrett-Conner, T.W. Weiss, S.G. Sajjan, and E. Siris An approach for identifying postmenopausal women age 50-64 years at increased short term risk for osteoporotic fracture Osteoporos Int 18 2007 1287 1296
12. P.D. Miller, S. Barlas, and S.K. Brenneman et al. An approach to identifying osteopenic women at increased short-term risk of fracture Arch Intern Med 164 2004 1113 1120
13. E. Siris, P. Miller, and E. Barrett-Connor et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA) JAMA 286 2001 2815 2822
14. J.A. Kanis, A. Oden, and O. Johnell et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women Osteoporos Int 18 2007 1033 1046
15. D.B. Hans, A.L. Goertzen, M.A. Krieg, and W.D. Leslie Bone microarchitecture by TBS predicts osteoporotic fractures independent of bone desnity: the Manitoba study J Bone Miner Res 26 11 2011 2762 2769
16. T.M. Keaveny Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans Ann NY Acad Sci 1192 2010 57 65
17. D. Krueger, D. Fidler, J. Libber, B. Aubier-Rozier, D. Hans, and N. Binkley Spine trabecular bone score subsequent to bone mineral density improves fracture discrimination in women J Clin Densitom 17 2014 60 65
18. K.E. Ensrud, L.Y. Lui, and B.C. Taylor et al. Renal function and risk of hip and vertebral fractures in older women Arch Intern Med 167 2007 133 139
19. L. Dukas, E. Schacht, and H.B. Stahelin In elderly men and women treated for osteoporosis a low creatinine clearance < 65 ml/min is a risk factor for falls and fractures Osteoporos Int 16 2005 1683 1690
20. L.F. Fried, M.L. Biggs, and M.G. Shlipak et al. Association of kidney function with incident hip fracture in older adults J Am Soc Nephrol 18 1 2007 282 286
21. T.L. Nickolas, S. Cremers, and A. Zhang et al. Discriminants of prevalent fractures in chronic kidney disease J Am Soc Nephrol 22 8 2011 1560 1567
22. T.L. Nickolas, M.B. Leonard, and E. Shane Chronic kidney disease and bone fracture: a growing concern Kidney Int 2 2008 1 11
23. A.M. Alem, D.J. Sherrard, and D.L. Gillen et al. Increased risk of hip fracture among patients with end-stage renal disease Kidney Int 58 2000 396 399
24. A.M. Ball, D.L. Gillen, and D. Sherrard et al. Risk of hip fracture among dialysis and renal transplant recipients JAMA 288 2002 3014 3018
25. M. Jadoul, J.M. Albert, and T. Akiba et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study Kidney Int 70 2006 1358 1366
26. C.O. Stehman-Breen, D.J. Sherrard, and A.M. Alem et al. Risk factors for hip fracture among patients with end-stage renal disease Kidney Int 58 2000 2200 2205
27. K.E. Ensrud Fracture risk in CKD Clin J Am Soc Nephrol 8 2013 1282 1283
28. S. Jamal, and P.D. Miller Secondary and tertiary hyperparathyroidism J Clin Densitom 16 1 2013 64 68
29. S.A. Jamal, S.L. West, and P.D. Miller Bone and kidney disease: diagnostic and therapeutic implications Curr Rheumatol Rep 14 2012 217 223
30. P.D. Miller Unrecognized and underappreciated secondary causes of osteoporosis Endocrinol Metab Clin North Am 41 3 2012 613 628
31. H. Jüppner, M. Wolf, and I.B. Salusky FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res 25 2010 2091 2097
32. D. Cejka, J. Herberth, and A.J. Branscum et al. Sclerostin and dikkopf-1 in renal osteodystrophy Clin J Am Soc Nephrol 6 4 2011 877 882
33. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Working Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 S130
34. A.M. Parfitt, M. Drezner, and F. Glorieux et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee J Bone Miner Res 2 6 1987 595 610
35. D.W. Dempster, J.E. Compston, and M.K. Dreznar et al. Standarized nomenclature, symbols, and units for bone histomorphonetry: an update of the report of the ASBMR histomorphometry nomenclature committee J Bone Miner Res 28 1 2013 2 17
36. D.L. Andress, and D.J. Sherrard The osteodystrophy of chronic renal failure R.W. Schrier, Diseases of the Kidney and Urinary Tract 2003 Lippincott Williams & Wilkins Philadelphia, PA 2735 2768
37. P.D. Miller The role of bone biopsy in chronic kidney disease Clin J Am Soc Nephrol 3 suppl 3 2008 S140 S150
38. H.M. Frost Tetracycline-based histological analysis of bone remodeling Calcif Tissue Res 3 3 1969 211 237
39. O. Hitt, Z.F. Jaworski, A.G. Shimizu, and H.M. Frost Tissue-level bone formation rates in chronic renal failure, measured by means of tetracycline bone labeling Can J Physiol Pharmacol 48 12 1970 824 828
40. A.M. Parfitt Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry Curr Opin Nephrol Hypertens 12 2003 387 403
41. D. Trueba, B.P. Sawaya, H. Mawad, and H.H. Malluche Bone biopsy: indications, techniques, and complications Semin Dial 16 4 2003 341 345
42. P.D. Miller, S.A. Jamal, P. Evenepoel, R. Eastell, and S. Boonen Renal safety in patients treated with bisphosphonates: a review J Bone Miner Res 28 10 2013 2049 2059
43. A. Gal-Moscovici, and S.M. Sprague Osteoporosis and chronic kidney disease Semin Dial 20 5 2007 423 430
44. E.J. Lamb, S. Vickery, and A.R. Ellis Parathyroid hormone, kidney disease, evidence and guidelines Ann Clin Biochem 7 2007 647 656
45. S. Jamal, S. West, and P.D. Miller Fracture risk assessment in patients with chronic kidney disease Osteoporos Int 23 2012 1191 1198
46. Zangeneh F, Clarke BL, Hurley DL, Watts NB, Miller PD. Chronic kidney disease mineral and bone disorder: what the endocrinologist needs to know [published online ahead of print July 24, 2013]. Endocr Pract. http://dx.doi.org/10.1038/ki.2013.271.
47. Y. Fang, C. Ginsburg, T. Sugatani, M.C. Monier-Faugere, H. Malluche, and K.A. Hruska Early chronic kidney disease-mineral bone disorder stimulates vascular calcification Kidney Int 85 1 2014 142 150
48. G.M. Kirsztajn, J.H. Suassuna, and M.G. Bastos Dividing stage 3 of chronic kidney disease (CKD): 3A and 3B Kidney Int 76 4 2009 462 463
49. ® in clinical practice J Clin Densitom 14 3 2013 226 236
50. B.F. Boyce Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts J Bone Miner Res 28 4 2013 711 722
51. F.M. Takyar, S. Tonna, and P. Ho et al. Ephrin B2,EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone J Bone Miner Res 28 4 2013 912 925
52. E. Canalis Wnt signaling in osteoporosis: mechanisms and novel therapeutic approaches Nat Rev Endocrinol 9 10 2013 573 583
53. Y. Rhee, E.Y. Lee, and V. Lezcano et al. Resorption controls bone anabolism driven by PTH receptor signaling in osteocytes J Biol Chem 288 41 2013 29809 29820
54. B. Boyce Advances in the regulation of osteoblasts and osteoclasts functions J Dent Res 92 10 2013 860 867
55. L. Bonewald The amazing osteocyte J Bone Miner Res 26 2 2011 229 238
56. K. Hernrisksen, Bonewald L. Neutzsky-Wulff, and M. Kardsal Local communication on and within the bone controls bone remodeling Bone 44 6 2009 1026 1033
57. L. Bonewald, and M.L. Johnson Osteocytes, mechanosensing and Wnt signaling Bone 42 4 2008 606 615
58. R. Eastell, and R.A. Hannon Biomarkers of bone health and osteoporosis risk Proc Nutr Soc 67 2008 157 162
59. R. Civitelli, R. Armamento-Villareal, and N. Napoli Bone turnover markers: understanding their value in clinical trials and clinical practice Osteoporos Int 20 2009 843 851
60. ® J Clin Densitom 14 3 2012 220 222
61. P.M. Chavassieux, and P.D. Delmas Bone remodeling: biochemical markers or bone biopsy? J Bone Miner Res 21 1 2006 178 179
62. A.L. Schafer, E. Vittinghoff, R. Ramachandran, N. Mahmoudi, and D.C. Bauer Laboratory reproducibility of biochemical markers of bone turnover in clinical practice Osteoporos Int 21 2010 439 445
63. S. Vasikaran, R. Eastell, O. Bruyère for the IOF-IFCC Bone Marker Standard Working Group Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards Osteoporos Int 22 2011 391 420
64. D.C. Bauer, E. Leary, and S. Silverman et al. National Bone Health Alliance Bone Marker Turnover Project: current practices and the need for U.S. harmonization, standardization and common reference ranges Osteoporos Int 2013 In press
65. G. Coen, P. Ballanti, and E. Bonnucci et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictively of intact PTH Nephron 91 2002 103 111
66. H.H. Malluche, and M.C. Manier-Faugere PTH fragmants and bone turnover Am J Kidney Dis 41 2003 1127
67. G. Coen, P. Ballanti, and E. Bonnucci et al. Bone markers in the diagnosis of low turnover osteodystrophy in hemodialysis patients Nephrol Dial Transplant 13 1998 2294 2302
68. M.M. Couttenye, P.C. D'Haese, and V.O. Van Hoof et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients Nephrol Dial Transplant 11 1996 1065 1072
69. D.J. Lemming, P. Alexandersen, M.A. Kardsal, P. Qvist, E.S. Schaller, and L.B. Tanko An update of biomarkers of bone turnover and their utility in biomedical research and clinical practice Eur J Clin Pharmacol 62 2006 781 792
70. Krege JH, Lane NE, Harris JM, Miller PD. PINP as a biological response marker during teriparatide treatment for osteoporosis [published online ahead of print March 6, 2014]. Osteoporos Int. http://dx.doi.org/10.1007/s00198-014- 2646-0.
71. C. Garrett, S. Sardiwal, E.J. Lamb, and D. Goldsmith PTH - a particularly tricky hormone: why measure it at all in kidney patients Clin J Am Soc Nephrol 8 2013 299 312
72. L.C. Hofbauer, C.C. Brueck, and S.K. Singh et al. Osteoporosis in patients with diabetes mellitus J Bone Miner Res 22 2007 1317 1328
73. A.M. Inzerillo, and S. Epstein Osteoporosis and diabetes mellitus Rev Endocr Metab Disord 5 2004 261 268
74. C.J. Rosen, and K.J. Motyl No bones about it: insulin modulates skeletal remodeling Cell 142 2 2010 198 200
75. G. Coen Adynamic bone disease: an update and overview J Nephrol 18 2005 117 122
76. J.M. Frazão, P. Martins, and P.D. Miller Osteoporosis in patients with chronic kidney disease: diagnosis, evaluation and management D.S. Basow, Up-to-Date 2013 UpToDate Waltham, MA
77. P.D. Miller Fragility fractures in chronic kidney disease: an opinion-based approach Cleve Clin J Med 76 2009 715 723
78. B. Ettinger, D.M. Black, and B.H. Mitlak et al. Reduction of vertebral fracture risk in post-menopausal women treated with raloxifene: results from a 3 year randomized clinical trial JAMA 282 1999 637 645
79. J.M. Kaufman, J.Y. Reginster, and S. Boonen et al. Treatment of osteoporosis in men Bone 53 1 2013 134 144
80. D. Bliuc, N.D. Nguyen, V.E. Milch, T.V. Nguyen, J.A. Eisman, and J.R. Center Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 5 2009 513 521
81. P.D. Miller Antiresorptives in the management of osteoporosis Best Pract Res Clin Endocrinol Metab 22 5 2008 849 868
82. R.G. Russell, N.B. Watts, F.H. Ebetino, and M.J. Rogers Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 6 2008 733 759
83. Diab DL, Watts NB, Miller PD. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Dempster D, Lucket M, Cauley J, eds. Osteoporosis 2013. 4th ed. Waltham, MA: Elsevier. 2013:1859-1872.
84. A. Luhe, K.P. Kunkele, and M. Haiker et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety Toxicol In Vitro 22 2008 899 909
85. P.D. Miller The kidney and bisphosphonates Bone 49 2011 77 81
86. G.S. Markowitz, P.L. Fine, and J.I. Stack et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa) Kidney Int 64 2003 281 289
87. P.D. Miller, S. Ragi-Eis, C. Mautalan, F. Ramimeriz, and I. Jonkamski Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease - the DIVINE study Bone 49 2011 1317 1322
88. L.S. Rosen, D. Gordon, and M. Kaminski et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 2003 1735 1744
89. F. Saad, D.M. Gleason, and R. Murray et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
90. S.A. Jamal, D.C. Bauer, and K.E. Ensrud et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial J Bone Miner Res 22 2007 503 508
91. P.D. Miller, C. Roux, S. Boonen, I.P. Barton, L.E. Dunlap, and D.E. Burgio Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials J Bone Miner Res 20 2005 2105 2115
92. M. Whitaker, J. Guo, T. Kehoe, and G. Benson Bisphosphosphonates for osteoporosis - where do we go from here? N Engl J Med 366 22 2012 2048 2051
93. E. Shane, D. Burr, and B. Abrahamason et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 29 1 2014 1 23
94. D.M. Black, A.V. Schwartz, K.E. Ensrud FLEX Research Group Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2006 2927 2938
95. S. Khosla, J.P. Bilezikian, and D.W. Dempster et al. Benefits and risks of bisphosphonate therapy for osteoporosis J Clin Endocrinol Metab 97 2012 2272 2282
96. M. McClung, S.T. Harris, and P.D. Miller et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday Am J Med 126 2013 13 20
97. P.N. Sambrook, I.D. Camerson, and J.S. Chen et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five year study Osteoporos Int 2 2011 2551-2256
98. B. Thompson, and D.A. Towler Arterial calcification and bone physiology: role of the bone-vascular axis Nat Rev Endocrinol 8 2012 529 543
99. P. Peris, E.J. Atkinson, and M. Gössl et al. Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women Mayo Clin Proc 88 1 2013 46 55
100. L.L. Santos, T.B. Cavalcanti, and F.A. Bandeira Vascular effects of bisphosphonates - a systematic review Clin Med Insights Endocrinol Diabetes 5 2012 47 54
101. K.A. Hruska, G. Saab, S. Mattew, and R. Lund Renal osteodystrophy, phosphate homeostasis, and vascular calcification Semin Dial 2007 309 315
102. P.D. Miller Denosumab-anti-RANK ligand antibody Curr Osteoporos Rep 7 2009 18 22
103. P.D. Miller Denosumab - a review Ther Adv Musculoskel Dis 3 6 2011 271 282
104. I.R. Reid, P.D. Miller, J.P. Brown on behalf of the Denosumab Phase 3 Bone Histology Study Group Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies J Bone Miner Res 25 2010 2256 2265
105. P.D. Miller, M.A. Bolognese, E.M. Lewiecki for the AMG 162 Bone Loss Study Group Long term efficacy and safety of denosumab treatment in postmenopausal women with low bone mass: 48 month results of a randomized phase II clinical trial Bone 43 2 2008 222 229
106. S.R. Cummings, J.A. Martin, M.R. McClung for the FREEDOM Trial Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 2009 756 765
107. M.R. McClung, E.M. Lewiecki, and M.A. Bolognese et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8 year results of a phase 2 clinical trial Osteoporos Int 24 1 2013 227 235
108. D.L. Kendler, C. Roux, and C.L. Benhamou et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate J Bone Miner Res 25 2010 72 81
109. G.A. Block, H.H. Bone, L. Fang, E. Lee, and D. Padhi A single-dose study of denosumab in patients with various degrees of renal impairment J Bone Miner Res 27 7 2012 1471 1479
110. S.A. Jamal, O. Ljunggren, and C. Stehman-Breen et al. The effects of denosumab on fracture and bone mineral density by level of kidney function J Bone Miner Res 2011 In press
111. West SL, Lok CE, Jamal SA. Osteoprotegerin and fractures in men and women with chronic kidney disease [published online ahead of print October 11, 2013]. J Bone Miner Metab. http://dx.doi.org/10.1007/s00774-013-0506-1.
112. P.J. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, P.T. Leese, and C.R. Dunstan The effect of a single dose of osteoprotogerin in postmenopausal women J Bone Miner Res 16 2 2001 348 360
113. E.J. Samelson, P.D. Miller, and C. Christiansen et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk J Bone Miner Res 29 2 2014 450 457
114. P.D. Miller, J.P. Bilezikian, C. Deal, and S.T. Harris Clinical use of teriparatide in the real world: initial insights Endocr Pract 10 2 2004 139 148
115. E.S. Orwoll, W.H. Scheele, and S. Paul et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis J Bone Miner Res 18 2003 9 17
116. E.S. Kurland, F. Cosman, D.J. McMahan, C.J. Rosen, R. Lindsay, and J.P. Bilizikian Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers J Clin Endocrinol Metab 85 2000 3069 3076
117. K.G. Saag, E. Shane, and S. Boonen et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis N Engl J Med 357 20 2007 2028 2039
118. J.P. Bilezikian, T. Matsumoto, and T. Bellido et al. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop J Bone Miner Res 24 3 2009 373 385
119. R.M. Neer, C.D. Arnaud, and J.R. Zanchetta et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
120. P.D. Miller, E.N. Schwartz, P. Chen, D.A. Misurski, and J.H. Krege Teriparatide in postmenopausal women with osteoporosis and impaired renal function Osteoporos Int 18 2007 59 68
121. D.W. Dempster, F. Cosman, and A.S. Kurland et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study J Bone Miner Res 16 2001 1846 1853
122. P. Chen, P.D. Miller, P.D. Delmas, D.A. Misurski, and J.K. Krege Change in bone mineral density (BMD) and fracture risk reduction in teriparatide-treated women with osteoporosis J Bone Miner Res 21 2006 1785 1790
123. J.B. Cannata-Andía, M. Rodriguez García, and C. Gómez Alonso Osteoporosis and adynamic bone in chronic kidney disease J Nephrol 26 2013 73 78
124. J.M. Frazao, and P. Martins Adynamic bone disease: clinical and therapeutic implications Curr Opin Nephrol Hypertens 18 4 2009 303 307
125. R. Lindsay, W.H. Scheele, and R. Neer et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide [recombinant human parathyroid hormone (1-34)] in postmenopausal women with osteoporosis Arch Intern Med 164 2004 2024 2030
126. J. Reginster, H.W. Minne, and O.H. Sorensen et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 1 2000 83 91
127. M.R. McClung, P. Geusens, and P.D. Miller et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 5 2001 333 340